Professor emeritus in the Department of Molecular Genetics of the Weizmann Institute of Science, and, since 2010, the Chief Scientist of Kadimastem, an Israeli company devoted to medical applications of human embryonic stem cells.Prof. Michel Revel an M.D. and Ph.D. degree from the University of Strasbourg, and joined the Weizmann Institute in Israel in 1968. Prof. Revel made fundamental contributions to understanding the mechanism of action of Interferons. In 1980, his group isolated the genes for human Interferon-beta and for Interleukin-6, and developed a genetic engineering method for constitutive production of such glycoproteins in mammalian cells. He was the founder and Chief Scientist of InterPharm, an Israeli company now integrated in the Merck Serono group, which developed human recombinant Interferon-beta, today a major drug for treating Multiple Sclerosis.
Revel’s recent research consisted of the differentiation of human embryonic stem (ES) cells into nerve-myelinating oligodendrocytes and into insulin-producing pancreatic endocrine cells. Kadimastem industrially develops these methods for medical applications in treating Diabetes, and for screening new drugs intended to stimulate remyelination in diseases such as Multiple Sclerosis.
Prof. Revel has received the Israel Prize in 1999 and the Emet Prize in 2004 for his contribution to Medicine and Biotechnology. He is member of the Israel Academy of Science and Humanities, has been elected Fellow of the New York Academy of Science, and Honorary Member of the International Society for Interferon and Cytokine Research. Prof. Revel is also member of the European Molecular Biology Organization (EMBO) and of the Human Genome Organization (HUGO). He was chairman of the National Biotechnology Committee for Israel (1999-2002) and chairman of the Israel National Bioethics Committee.